{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T12:09:51Z","timestamp":1744114191507},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T00:00:00Z","timestamp":1557878400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T00:00:00Z","timestamp":1557878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s00108-019-0614-7","type":"journal-article","created":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T21:10:35Z","timestamp":1557954635000},"page":"690-700","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Infektionen des zentralen Nervensystems bei Immundefizienz"],"prefix":"10.1007","volume":"60","author":[{"given":"K.","family":"Angstwurm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,15]]},"reference":[{"key":"614_CR1","volume-title":"Empfehlungen zur diagnoseorientierten Auswahl von Untersuchungsmethoden in der Liquordiagnostik: Leitlinie der Liquordiagnostik, Deutschen Gesellschaft f\u00fcr Liquordiagnostik und Neurochemie","author":"Adelmann","year":"2019","unstructured":"Adelmann et\u00a0al (2019) Empfehlungen zur diagnoseorientierten Auswahl von Untersuchungsmethoden in der Liquordiagnostik: Leitlinie der Liquordiagnostik, Deutschen Gesellschaft f\u00fcr Liquordiagnostik und Neurochemie. \n                    https:\/\/docs.wixstatic.com\/ugd\/92c932_d9bea73b5794461eac58bdc7d094ec03.pdf\n                    \n                  . Zugegriffen: 18. Febr. 2019"},{"key":"614_CR2","volume-title":"Diagnostik und Therapie HIV-1-assoziierter neurologischer Erkrankungen. Leitlinie der Deutschen Gesellschaft f\u00fcr Neurologie","author":"G Arendt","year":"2012","unstructured":"Arendt G et al (2012) Diagnostik und Therapie HIV-1-assoziierter neurologischer Erkrankungen. Leitlinie der Deutschen Gesellschaft f\u00fcr Neurologie. \n                    https:\/\/www.dgn.org\/images\/red_leitlinien\/LL_2012\/pdf\/030-044l_S1_HIV-1_assoziierte_Erkrankungen_2013_verlaengert.pdf\n                    \n                  . Zugegriffen: 18. Febr. 2019"},{"key":"614_CR3","first-page":"598","volume-title":"Therapie und Verlauf neurologischer Erkrankungen","author":"G Arendt","year":"2012","unstructured":"Arendt G, Maschke (2012) HIV-Infektion und AIDS: neurologische Manifestationen. In: Brandt T, Diener HC, Gerloff C (Hrsg) Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, S 598\u2013624"},{"key":"614_CR4","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1056\/NEJMra1301635","volume":"371","author":"MC Brouwer","year":"2014","unstructured":"Brouwer MC, Tunkel AR, McKhann GM, van de Beek D (2014) Brain abscess. N Engl J Med 371:447\u2013456","journal-title":"N. Engl. J. Med."},{"key":"614_CR5","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/0140-6736(93)92814-A","volume":"342","author":"P Cinque","year":"1993","unstructured":"Cinque P, Brytting M, Vago L, Castagna A, Parravicini C, Zanchetta N, D\u2019Arminio Monforte A, Wahren B, Lazzarin A, Linde A (1993) Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system. Lancet 342:398\u2013401","journal-title":"Lancet"},{"key":"614_CR6","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/S1473-3099(10)70222-X","volume":"10","author":"J Granerod","year":"2010","unstructured":"Granerod J, Ambrose HE, Davies NW, Clewley JP, Walsh AL, Morgan D, Cunningham R, Zuckerman M, Mutton KJ, Solomon T, Ward KN, Lunn MP, Irani SR, Vincent A, Brown DW, Crowcroft NS, UK Health Protection Agency (HPA) Aetiology of Encephalitis Study Group (2010) Causes of encephalitis and differences in their clinical presentations in England: a\u00a0multicentre, population-based prospective study. Lancet Infect Dis 10:835\u2013844","journal-title":"Lancet Infect Dis"},{"key":"614_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1086\/313603","volume":"30","author":"JR Graybill","year":"2000","unstructured":"Graybill JR, Sobel J, Saag M, van Der HC, Powderly W, Cloud G, Riser L, Hamill R, Dismukes W (2000) Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis 30:47\u201354","journal-title":"Clin. Infect. Dis."},{"key":"614_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1056\/NEJM199707033370103","volume":"337","author":"CM van der Horst","year":"1997","unstructured":"van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, Johnson PC, Tuazon CU, Kerkering T, Moskovitz BL, Powderly WG, Dismukes WE (1997) Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 337:15\u201321","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"614_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jinf.2016.09.007","volume":"74","author":"U Khatib","year":"2017","unstructured":"Khatib U, van de Beek D, Lees JA, Brouwer MC (2017) Adults with suspected central nervous system infection: a prospective study of diagnostic accuracy. J\u00a0Infect 74(1):1\u20139","journal-title":"J Infect"},{"key":"614_CR10","first-page":"570","volume-title":"Therapie und Verlauf neurologischer Erkrankungen","author":"M Maschke","year":"2012","unstructured":"Maschke M (2012) Virale Entz\u00fcndungen des ZNS. In: Brandt T, Diener HC, Gerloff C (Hrsg) Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, S\u00a0570\u2013581"},{"key":"614_CR11","volume-title":"Virale Meningoenzephalitis. Leitlinie der Deutschen Gesellschaft f\u00fcr Neurologie","author":"Meyding-Lamad\u00e9","year":"2018","unstructured":"Meyding-Lamad\u00e9 et al (2018) Virale Meningoenzephalitis. Leitlinie der Deutschen Gesellschaft f\u00fcr Neurologie. \n                    https:\/\/www.dgn.org\/images\/red_leitlinien\/LL_2018\/PDFs_Download\/030100_LL_Virale_Meningoenzephalitis_2018.pdf\n                    \n                  . Zugegriffen: 18. Febr. 2019"},{"key":"614_CR12","volume-title":"Hirnabszess. Leitlinie der Deutschen Gesellschaft f\u00fcr Neurologie","author":"R Nau","year":"2016","unstructured":"Nau R et\u00a0al (2016) Hirnabszess. Leitlinie der Deutschen Gesellschaft f\u00fcr Neurologie. \n                    https:\/\/www.dgn.org\/images\/red_leitlinien\/LL_2016\/PDFs_Download\/030108_LL_Hirnabszess_2016.pdf\n                    \n                  . Zugegriffen: 18. Febr. 2019"},{"key":"614_CR13","unstructured":"Pfister HW et\u00a0al (2015) Ambulant erworbene bakterielle (eitrige) Meningoenzephalitis im Erwachsenenalter. Leitlinie der Deutschen Gesellschaft f\u00fcr Neurologie. \n                    https:\/\/www.dgn.org\/images\/red_leitlinien\/LL_2015\/PDFs_Download\/030-089l_S2k_Ambulant_erworbene_Meningoenzephalitis_2016-08-verlaengert_01.pdf\n                    \n                  . Zugegriffen: 18. Febr. 2019"},{"key":"614_CR14","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1056\/NEJMra1708714","volume":"379","author":"KL Tyler","year":"2018","unstructured":"Tyler KL (2018) Acute viral Encephalitis. N Engl J Med 379:557\u2013566","journal-title":"N. Engl. J. Med."}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-019-0614-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-019-0614-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-019-0614-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T23:11:14Z","timestamp":1589411474000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-019-0614-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,15]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["614"],"URL":"https:\/\/doi.org\/10.1007\/s00108-019-0614-7","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,15]]},"assertion":[{"value":"15 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"K.\u00a0Angstwurm erhielt 2009 bis 2014 Unterst\u00fctzung f\u00fcr Reisen von Alexion, Bayer, Biogen Idec, Merck Serono, Novartis und Teva und nimmt seit 2009 an klinischen Studien zu neuroimmunologischen Erkrankungen teil f\u00fcr Alexion, Bayer Schering, Biogen Idec, Merck Serono, Novartis und Roche. B.\u00a0Neumann gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}